SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: High Dose SAB-142
DRUG: Low Dose SAB-142
OTHER: Placebo

Sponsor

SAb Biotherapeutics, Inc.